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Receptor  Antagonist  After  Intravenous  Immunoglobulin 
Administration In Vivo 
By Pi1 Aukrust,  Stig S.  Frcbland,  Nina-Beate Liabakk, Fredrik Muller,  lngvild  Nordcby, Charlotte Haug, 
and Terje  Espevik 
We investigated the in vivo  effects  of  one  bolus  injection 
(400  mg/kg)  of intravenous  immunoglobulin  (IVIG) on  a 
number  of  cytokines,  soluble  cytokine  receptors,  and  in- 
terleukin-l receptor  antagonist  (IL-1Ra)  in  plasma  in 12  pa- 
tients with primary  hypogammaglobulinemia.  A  significant 
and  rapid  increase  in plasma  levels  of  11-6. IL-8,  and  tumor 
necrosis  factor a  (TNFa) was seen within 1 hour  after  IVlG 
infusion.  This  increase  was accompanied  by  a  more  pro- 
longed  elevation  in  levels  of both types  of soluble  TNF  recep- 
tors  (sTNFRs),  which  remained  elevated  throughout  the 
study  period  (44  hours)  although  they  reached  peak  levels 
within 1  hour.  After  an initial increase in the ratio between 
REATMENT  WITH  intravenous  immunoglobulin 
(IVIG) is used  not  only  for patients with primary or 
secondary hypogammaglobulinemia, but also increasingly in 
a number of  noninfectious immune-mediated disorders (eg, 
autoimmune thrombocytopenic purpura, myasthenia gravis, 
Kawasaki disease, and systemic lupus erythematosus'). Al- 
though data from several trials suggest its effectiveness in 
many of  these disorders,' little is known about the mecha- 
nisms of  action of  IVIG.'.'  Several nonmutually exclusive 
mechanisms have been postulated, eg, blockade of Fc-recep- 
tor  function of  phagocytic cells,  inhibition of  production 
and/or neutralization of  pathogenic autoantibodies possibly 
mediated by anti-idiotypic antibodies, changes in distribution 
and function of  T-cell subsets, and antigen-specific immune 
suppression through antimicrobial or  antiautoantigen anti- 
bodie~."~ 
Altered cytokine production may be involved in the patho- 
genesis of  several  autoimmune disorders:  and  therefore, 
modulation of abnormal cytokine production may contribute 
to  the therapeutic effects of  IVIG in  these diseases.','  In 
vitro studies suggest that IVIG has direct effects on cytokine 
production in T-cells and monocyte/macrophages.5~*  How- 
ever, in vitro experiments may  not  reflect  the much more 
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TNFa  and  sTNFRs,  this ratio decreased to values  signifi- 
cantly  lower  than  baseline  values  20 and 44 hours  postinfu- 
sion with -600-fold  molar  excess of  sTNFRs  to TNFa (tri- 
mer). Although  only  a  modest  but statistically  significant 
increase in plasma levels of  IL-1fi  was seen,  IVlG infusion 
was  followed  by  a  marked  increase  in plasma  levels  of  IL- 
1Ra with 1,000-fold  molar  excess of IL-1Ra to  IL-lfi  in some 
patients.  The  demonstrated  effects of IVlG  infusion  on the 
cytokine  network,  particularly  the induction  of  IL-1Ra  and 
sTNFRs  release, might  be  important  for the therapeutic ef- 
fects  of  WIG  in several immune-mediated  disorders. 
0  1994 by The  American  Society  of Hematology. 
complicated situation in  vivo, and  very  few  studies have 
addressed the influence of IVIG on circulating cytokine lev- 
els? Furthermore, accumulating evidence indicates that bio- 
logic effects of  a cytokine in vivo may  be  modulated not 
only  by  its  soluble receptors and receptor antagonist, but 
also by other cytokines.'o*'' Therefore, in the present study, 
we investigated the effects of IVIG on plasma concentrations 
of  a number of  cytokines, soluble cytokine receptors, and 
interleukin-l  receptor antagonist (L-1Ra) in patients with 
primary hypogammaglobulinemia. 
MATERIALS  AND  METHODS 
Study popularion.  Twelve patients (4  men  and 8 women;  median 
age, 39 years; range, 20 to 66 years) under treatment at the Section 
of Clinical Immunology and Infectious Diseases (Medical Depart- 
ment  A,  The National Hospital, Oslo, Norway) with the diagnosis 
of primary hypogammaglobulinemia  based on established 
were included in the study. Ten patients were classified as common 
variable immunodeficiency and two as congenital hypogammaglob- 
ulinemia as previously described.I4.l5  All patients had  been  treated 
with subcutaneous self-administered Ig for a minimum of 15 months 
and all had serum IgG levels greater than 5.0 g/L  before the study. 
No patients had  shown any signs of overt infection during the last 
3 weeks before blood collection. None were taking antibiotics or 
immunosuppressive drugs except for one patient who received tetra- 
cyclines because of  rosacea. At  the time of the study, serum level 
of  alanine aminotransferase was greater than  55 U/L  and  serum 
creatinine level less than  100 pmol/L in all patients. 
lg preparation.  Octagam (Octapharma, Vienna, Austria) is  a 
liquid virus-inactivated IVIG preparation (pH 4)  produced from Nor- 
wegian fresh frozen plasma collected in Norwegian blood banks. 
The final product is dispensed in sterile water containing 10% malt- 
ose (final  IgG  concentration, 5  g/L;  IgA and IgM, less than  0.1 g/ 
L). Each portion has been tested and found negative for antibodies 
to  human  immunodeficiency virus and hepatitis B and C virus. The 
endotoxin level in the IVIG preparation was less than  10 pg/mL 
(limulus amebocyte lysate test). 
Study design.  The study was part of  an Octagam tolerance and 
half-life study performed at Section of  Clinical Immunology and 
Infectious Diseases. When entering the trial, the patients underwent 
a careful clinical, hematologic, and biochemical investigation. All 
patients received a single infusion of  Octagam (0.4  @g)  by  slow 
intravenous infusion using an infusion set with filter (median total 
infusion time 3.2 hours; range, 2.7 to 4  hours). The patients were 
clinically followed during infusion and  until  6 hours postinfusion. 
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Blood samples for plasma collection were taken preinfusion and 
postinfusion 1, 3,20, and 44 hours. The study was approved by the 
Regional Ethical Committee and by the Norwegian Medicines Con- 
trol Authority (Statens Leggemiddelkomite, SLK). Signed informed 
consent was obtained from each patient before entering the study. 
Blood  sampling protocol.  Blood was drawn into sterile pyrogen- 
free vacuum blood collection tubes (Sarstedt, Numbrecht, Germany) 
using heparin (15 U/mL blood) as anticoagulant. Blood was immedi- 
ately immersed in melting ice and the tubes were centrifuged within 
20 minutes (400g and  4°C  for 10 minutes). Plasma was then trans- 
ferred in sterile Eppendorf tubes (Treff AG, Degersheim, Switzer- 
land) and further centrifuged at 10,OOOg  and 4°C for 5 minutes to 
obtain platelet-free plasma. Plasma was stored at ‘70°C in multiple 
aliquots until analysis (median storage time, 10 weeks; range, 1 to 
22 weeks). Samples were frozen and thawed only once. To minimize 
the variability, all samples from a given patient were run at  the same 
time (on  the  same microtiter enzyme immunoassay [EIA] plate). 
Immunoassays for detection of  soluble  tumor  necrosis factor re- 
ceptors (TNFRs) in plasma.  The soluble TNFRs (sTNFRs), p55 
and p75, were analyzed by immunoassays described by  Liabakk et 
Briefly, immunoplates were coated with the monoclonal anti- 
bodies (MoAbs) IV4E and 3H5, recognizing non-TNF-binding  sites 
of  p55- and p75 TNFR, respectively. Recombinant human (rhu) p55- 
and  p75  TNFR (provided by  Dr  H.  Loetscher, F.  Hoffmann-La 
Roche, Basel, Switzerland) served as standards. Bound sTNFRs were 
detected with digoxigenin (DIG)-labeled TNF, anti-DIG Fab frag- 
ments and o-phenylendiamine as substrate. The detection limit was 
300 pg/mL for both receptor assays. The intraassay and interassay 
coefficients of  variation were less than  10% for both assays. The 
specificity of the assays was controlled by inhibition with unlabeled 
rhuTNFa together with DIG-labeled TNF. The combination of anti- 
bodies recognizing non-TNF-binding  sites of  sTNFRs with  DIG- 
labeled TNF makes detection of free as well as reversibly occupied 
sTNFRs possible, because addition of excess DIG-labeled TNF dis- 
place TNF bound  in  complex to sTNFRs. The presence of  10 ngl 
mL of TNFa in a sample did not influence the results, suggesting 
that the assay is not affected by  the presence of TNFa in plasma 
samples even in pathologic conditions known  to  be  associated with 
very high circulating TNFa levels (eg, severe meningococcemia). 
Other  immunoassays.  Plasma concentration of cytokines, solu- 
ble IL-6Rs (sIL-~Rs),  and IL-IRa was quantified by EIAs provided 
from Medgenix (Fleurus, Belgium) (IL-lp, IL-6, TNFa, and inter- 
feron y  [IFNy]) and Quantikine, R & D (Minneapolis, MN) (IL-4, 
IL-8, IL-IRa,  sIL-6R) according to the manufacturer’s guidelines, 
using microtiter wells coated with one (Quantikine) or several (Med- 
genix) MoAbs against distinct epitopes of  the actual cytokine. The 
recombinant  IL-1Ra  standard  was  provided  from  Synergen  Inc 
(Boulder, CO). Samples with high levels of TNFcr or IL-1Ra were 
diluted and reassayed, and in the sIL-6R EIA, all samples were run 
in two dilutions (MO  and  11100).  The IL-6 and TNFa EIAs detect 
free IL-6 and TNFa as well as these cytokines bound  to their soluble 
receptors”  (manufacturer’s information). There was no cross-reac- 
tivity in the EIAs between the measured parameters or with other 
known cytokines or soluble cytokine receptors (manufacturer’s in- 
formation). In all EIAs, samples and recombinant standards (n = 7) 
were run  in  duplicate, and the optical density (OD) measured in a 
Multiskan  Multisoft photometer (Labsystems, Helsinki, Finland). 
The standard curve for each plate was obtained by fitting the average 
OD readings for the standards to a third order polynomial, and the 
concentrations of  the samples were determined from the obtained 
standard curve (ELISA+  software, Meddata Inc,  New  York, NY). 
According to the manufacturer’s instructions, the lower detection 
limits of  the EIA kits were 2 pg/mL (IL-lg),  4.1  pg/mL  (IL-4), 3 
pg/mL  (IL-6),  18.1 pg/mL (L-8), 0.03 IU/mL (IFNy), 3 
(TNFa), 22.0 pg/mL (E-IRa), and 350 pglmL (sIL-~R,  when as- 
sayed in a 100-fold dilution), and at our laboratory, the lowest stan- 
dard used was equal to  the detection limit. The intraassay and in- 
terassay coefficients of variation for all assays were less than 10%. 
Statistical  analysis.  For comparison of  plasma concentrations 
after WIG infusion with baseline levels the nonparametric Wilcoxon 
Matched Pairs Test was used. Coefficients of  correlation (r) were 
calculated by  the Spearman rank test. The calculations were per- 
formed using the  Statistical Analysis System (SAS Institute Inc, 
Cary, NC) and STATISTICAMac (StatSoft, Tulsa, OK) software 
packages. In the text, peak level is defined as the highest measured 
absolute concentration, and maximum change is defined as the  mea- 
sured concentration deviating maximally from baseline level -  base- 
line concentration. Data are  given  as medians and  25th to  75th 
percentiles if not otherwise stated. P values are two sided and consid- 
ered significant when P  < .05. 
RESULTS 
Cytokine  levels  in  IVIG preparation.  Using  the EIAs 
described above, we could not detect any amount of IL-lP, 
IL-4, IL-6,  IL-8,  TNFa, IFN-g, IL-lRa, or sTNFRs in the 
IVIG product used during the study. Soluble E-6R could 
be detected in very  low  concentrations (510 pg/mL),  well 
below  both  the lowest baseline value in the patients (25.5 
ng/mL) and the lowest detectable level in 40 healthy blood 
donors (13.5 ng/mL, manufactureis information). 
Cyokine  responses  afer  IVIG infusion.  As shown in Fig 
l,  there was a significant increase in plasma levels of IL-6, 
IL-8, and TNFa after IVIG administration. All patients had 
an increase in circulating IL-8 level and all but one, who 
had  a markedly elevated baseline level of  TNFa, had an 
increase in circulating IL-6 and TNFa levels. However, the 
kinetics of these cytokine changes were somewhat different 
(Fig 1). Thus, 7 of  12 patients reached peak level for IL-6 
after 1 hour, whereas IL-8 peaked in nine patients 3 hours 
postinfusion. Although the highest median TNFa level was 
reached 3 hours postinfusion, seven patients, including those 
two  with  the  most  pronounced increase in  plasma  level, 
reached peak level after 1 hour. After 3 hours, there was a 
decline in circulating levels of  these cytokines, but plasma 
levels of IL-6 and IL-8 in contrast to TNFa concentrations 
were still significantly increased compared with baseline val- 
ues after 20 hours (Fig 1). 
There was a slight, but significant increase in circulating 
IL-lP level (0 pg/mL  [0 to 0 pg/mL] versus 4 pg/mL  [0 
to 7 pg/mL], P < .05, baseline and 3 hours postinfusion, 
respectively).  However,  five  patients  had  undetectable 
plasma levels throughout the study. 
Although there was a slight increase in the median IFNy 
level  after infusion, the  differences from baseline  values 
were not statistically significant (Fig l). IVIG infusion did 
not induce any significant changes in plasma level of  IL-4, 
and  most  patients had undetectable plasma levels throughout 
the study (data not shown). 
IL-IRa response  afer WIG infusion.  As illustrated in 
Fig  1, there was  a marked increase in circulating IL-1Ra 
concentration after IVIG infusion. All patients had  an  in- 
crease in plasma levels with peak level at 1 hour postinfusion 
(1 1 of 12  patients). IL- l Ra levels returned rapidly to baseline 
values (Fig 1). 
Plasma  levels of  soluble  cytokine  receptors afer WIG 
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infusion.  In contrast with circulating L-lRa,  plasma levels 
of sTNFRs and sIL-6R showed a more prolonged elevation 
after IVIG infusion (Fig 1).  Soluble TNFRs showed a sig- 
nificant and rapid increase in circulating levels with peak 
values at 1 hour postinfusion for 7 of 12 and 6 of 12 patients, 
p55 and p75 receptors, respectively, and plasma concentra- 
tions remained elevated throughout the observation period 
(44  hours) (Fig 1). Only 2 patients did not show an increase 
in plasma levels for both types of sTNFRs (1 with markedly 
inreased baseline levels for both  sTNFRs, and  1  with  an 
increase only in p75 level after IVIG infusion). 
There  was  a  persistent, but  not  significant increase in 
plasma  levels of  sIL-6R after IVIG infusion (Fig  1) and 
except for the two patients with the highest baseline concen- 
trations, an increase was observed in all patients. 
Balance between TNFa and sTNFRs afer WIG  infusion. 
The ratio between TNFa and the sTNFRs may provide an 
estimate of the balance in plasma between TNF molecules 
and sTNFRs. In molecular terms, this ratio was  defined  as 
immunoreactive TNFa  (pmolL)/(p55  + p75)(pmoVL)  X 
100, assuming a molecular mass of  17  X  3 kD and 30 kD 
for TNFa (trimer) and both types of sTNFRs, respectively. 
Thus,  a  ratio less than 0.2 reflects a  more than 500-fold 
molar excess of sTNFRs to TNFa (trimer). When analyzing 
patients with  a  detectable TNFa level at baseline (n = 7), 
there  was  a  significant increase in this defined ratio at  1 
hour  postinfusion  (Fig 2). However,  at  20  and 44 hours 
postinfusion, a significant decrease was observed compared 
with baseline values, with -600-fold  molar excess (median) 
of sTNFRs at 44 hours postinfusion (Fig 2) 
Correlations  between  plasma  levels  of cytokines and their 
soluble  cytokine receptors afer WIG infusion.  As shown 
in Table 1, the maximum changes in plasma level of TNFa 
were  strongly  positively  correlated  with  the  maximum 
changes in plasma levels of  both types of  sTNFRs. More- 
over, the increase in p75 and p55 concentrations was signifi- 
cantly positively intercorrelated (Table 1). However, when 
analyzing the correlations between TNFa concentration and 
sTNFRs levels at various time points, only p75 levels were 
significantly correlated with the TNFa values (Table 2). 
In contrast with  the strong positive correlation between 
maximum changes in TNFa and sTNFRs levels, no signifi- 
cant correlation was found between IL-6 and sL-6R (Table 
Correlations  between changes in plasma levels of IL-1Ra 
and  other parameters.  The maximum change in IL-1Ra 
level was positively correlated with the maximum changes 
in all measured TNF parameters (Table l). No significant 
correlation was found between maximum changes in L-1Ra 
and IL-lP concentrations (data not shown). 
Correlations  between  plasma  levels of d@erent cytokines 
afer WIG infusion.  The  maximum  changes  in  TNFa 
plasma level tended to be positively correlated with the maxi- 
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Fig 2.  The  balance  between circulating  TNFa and sTNFRs at base- 
line and after WIG  infusion  expressed  as  TNFa (trimer) (pmol/L)/(p55 
+ p75)(pmol/L) x  100. Only patients with detoctable TNFa levels at 
baseline are included in = 7). (A) Data are  given  as medians  and  25th 
to 75th percentiles. (B) Data are given  for  each  individual  patient. *P 
< .05  versus  baseline. 
mum changes in IL-6 and IL-8 concentrations (Table 1). In 
contrast to TNFa, increase in IFNy plasma level seems to 
be negatively correlated with increases in the other measured 
parameters, and  this negative correlation was  statistically 
significant for L-8 and sIL-6R (Table 1). 
DISCUSSION 
The present study clearly shows that IVIG administration 
in vivo may have a number of effects on the cytokine net- 
work as reflected in plasma concentrations of cytokines and 
soluble cytokine receptors. Thus,  IVIG infusion was  fol- 
lowed by  a significant increase in proinflammatory cytokines 
(eg, L-8 and TNFa) as well as cytokine mediators with 
Fig 1.  Plasma  levels  of IL-6 (Al.  11-8  (B), TNFa (C), IFNy(D1,  IL-1Ra  (E), slLdR (F), and  sTNFRs  [soluble  p55 (G) and p75 (H) receptors] at 
baseline  and  after WIG infusion in 12 patients with primary  hypogammaglobulinemia.  Data are  given as medians  and  25th to 75th percentiles. 
*P < .05  versus  baseline, **P < .Ol versus  baseline, ***P < ,001 versus  baseline. 
~~ 
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Tabla 1. Correlations (r) Between  Maximum Changes in Plasma Leval.  of Different Cytokines 
and Soluble Moklne  RowDtors After lVl0 Infusion 
TNFa  11-6  IL-a  IFNy  p55 Receptor  p75 Receptor  slL-GR  IL-1Ra 
TNFa  .47  .47  -.l9  .65*  .73t  -.03  .63* 
IL-6  -.l1  .l9  .68*  .46  .03  .l6 
IL-8  -.68*  .o 1  26  .32  55 
IFNy  .03  -.l6  -.61*  -  .38 
Soluble p55 receptor  .75t  -.44  .63* 
Soluble p75 receptor  -.24  .52 
dL-6R  -.08 
* P < .05. 
t P<  .01. 
anti-inflammatory properties (eg, IL-lRa, sTNFRs, and IL- 
6). 
Several effects of  IVIG  administration  were  seen  on  the 
various  components of the TNFa system. Soluble TNFRs are 
released from different cell types after  proteolytic  cleavage 
of  the  membrane  TNFRs.'8-z'  The mechanisms  controlling 
TNFRs shedding have not  been fully elucidated.  However, it 
has been  suggested  that  both  TNFa and  stimuli  causing TNFa 
release also induce shedding of  s~.'9~20~z2  Thus, sTNFRs 
in  plasmalserum  are  thought  to  indicate  activation  of  the 
TNFa  with  elevated  concentration  persisting  for 
a  longer  time than TNFa  after stimulation."  In the  present 
study there was a  significant  positive  correlation  between  the 
maximum change in TNFa  and the levels of  both types of 
sTNFRs after  IVIG  infusion.  Others have previously  shown 
a  positive  correlation  beween  peak  levels of these parameters 
in  patients  with  septicemia2z.25  and  in patients  with  severe 
malaria.26  Furthermore, TNFa stimulation  in  vitro''  as well 
as in vivoz7  has  been  shown  to induce sTNFRs release.  How- 
ever, we  observed  that  whereas  plasma levels of  soluble p75 
receptor were significantly correlated to TNFa levels at base- 
line as well as at other time  points, no significant  correlation 
was  shown  between  concentrations of  soluble p55  receptor 
and TNFa at any  time  points,  possibly  reflecting  differences 
in  kinetics  and regulation of  these two types of  sTNFRs, as 
has  recently  been  suggested  by ~thers?~.'~ 
Although there was a statistically significant increase in 
plasma  levels of  IL-l@ after IVIG infusion in the whole 
group, this increase was very modest. In contrast, IVIG infu- 
sion was followed by  a marked increase in plasma levels of 
IL-lRa, the structurally related, naturally occurring antago- 
nist of  IL-l.30 To our knowledge, the present report is the 
first published demonstration of induction of increased circu- 
lating IL-1Ra levels by  IVIG infusion. 
Although the correlation between the increase in IL-1Ra 
and soluble p75 receptor did not reach statistical significance, 
we  found  a  positive  correlation  between  the  maximum 
change in IL-1Ra concentration and the maximum changes 
in TNFa and sTNFRs levels. Our findings may  merely  reflect 
correlation between  different parameters of  WIG-induced 
monocyte  hyperactivity  because  monocytes  are  a  major 
source for both IL-1Ra and TNFa produ~tion.4*~~  On  the 
other hand, these correlations may  reflect common inducing 
mechanisms for the release of these mediators after IVIG 
infusion. Interestingly, Mazzei et  a13'  have suggested that 
TNFa may  be  implicated in  the  IL-1Ra production in  a 
promyelocytic cell line, possibly via induction of  GM-CSF, 
and a  very  recent study has shown that TNFa greatly aug- 
mented IL-1Ra transcripts in neutrophils that may contribute 
to the circulating IL-1Ra levels.3z 
We did  not  investigate the mechanisms of  the cytokine 
modulating effects of IVIG administration in vivo. However, 
it is conceivable that some of  the effects are mediated by 
interaction of  immune complexes or IgG with Fc-receptors 
on monocytes5" as well other cell types, eg, neutrophils and 
NK-~ells.~~  IgG prepared from pooled plasma may spontane- 
ously dimerize by anti-idiotypic interactions," and antigens 
present in the body  may form immune complexes with anti- 
bodies in IVIG. Previous in vitro studies have shown that 
both immune complexes and IgG are potent stimulants of 
IL-1Ra  production in  monocytes without affecting IL-lP 
relea~e.~~.~~  Immune complexes have  also been  shown to 
induce production of  and IL-638  in monocytes and 
IFNy in NK-cells3' via Fc-receptor interaction. Other mecha- 
nisms may involve cytokine antibodies"  and  other immuno- 
modulating factors (eg, sCD4, sCD8, sHLA  antigen^)^'  in 
IVIG preparations. However, in the IVIG preparation used in 
the present study, we could neither detect sCD8 (unpublished 
Tabla 2.  Codations (r) Between Pluma bv.h  of TNFa and sTNFR. (p65 and p75 receptor) at Barline 
and at Various Time Points After IVlG Infuaion 
Correlation Between  lh  3h  20 h  44 h 
TNFa and  Baseline  Postinfusion  Postinfusion  Postinfusion  Postinfusion 
Soluble p55  receptor  .44  .38  .55  .36  .26 
Soluble p75  receptor  .85*  .78t  .83*  .74t  .63$ 
P  < .002. 
t P < .01. 
* P < .05. 
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results, May 1993) nor cytokines and soluble cytokine recep- 
torsh-eceptor antagonist except for small amounts of sIL-6R. 
The demonstrated effects of IVIG on the circulating cytok- 
ine network may  be relevant for the  clinically significant 
immunomodulating effects of  IVIG therapy seen in many 
disorders.' The proinflammatory cytokines IL-1 and TNFa 
play  an  important role in many autoimmune diseases:  and 
therefore, suppression of the activity of these cytokines may 
be an important therapeutic goal in such disorders. Although 
there was an initial increase in the plasma levels of TNFa 
and IL-lp, this increase was accompanied by  an increase in 
levels of  both types of  sTNFRs as well as IL-1Ra. Further- 
more, plasma levels of  sTNFRs remained persistently ele- 
vated during the whole study period of 44 hours in contrast 
with TNFa  levels. Soluble TNFRs may neutralize TNFa in 
vitro''  and  sTNFRs have  recently been  shown to  protect 
mice from lethal effects of  endotoxic shock."  Based on such 
observations, it has been suggested that the degree of  bio- 
logic TNFa activity may  depend on the balance between 
TNFa and  STNFRS.~~,~'  In the present study, we observed 
that after an initial increase in the ratio between TNFa and 
sTNFRs, this ratio 20 and 44 hours postinfusion decreased 
to values significantly lower than baseline values with -600- 
fold molar excess of sTNFRs to  TNFa  (trimer). It is conceiv- 
able that such a degree of  sTNFRs excess may mediate an 
inhibition of TNFa-mediated cytotoxicity." 
Also, the  increased levels of  IL-1Ra found  after IVIG 
infusion may be of clinical relevance. When comparing peak 
levels, a  1000-fold molar excess of  IL-1Ra to IL-1p was 
found in some patients. A  10-fold molar excess of  IL-1Ra 
is  required  for  inhibition  of  IL-1-induced  responses  in 
monocytes in vitro, whereas IL-1Ra to IL-1p ratios greater 
than lo4  are needed to block IL-1 effects in vivo.438"  Thus, 
the in vivo effects of the increased IL-1Ra levels after IVIG 
infusion are uncertain. 
Increased levels of IL-6, IFNy,  and sIL-6R were observed 
after IVIG infusion, even if only the increase in L-6  levels 
reached statistical significance. These changes may also be 
of some interest with reference to immunomodulating effects 
of WIG therapy. Although IL-6 shares several biologic fea- 
tures with TNFa and IL-1:  this cytokine also has anti-in- 
flammatory proper tie^.^^ Thus, IL-6 has been shown to sup- 
press  lipopolysaccharide  &PS)-induced  TNF  and  IL-1 
production.46  Increased levels of  sIL-6R might contribute to 
such anti-inflammatory effects because sIL-~R,  in contrast 
to other soluble cytokine receptors, has agonistic properties 
together with its ligand!7  Furthermore, IFNy may also ex- 
hibit  anti-inflammatory properties  and  has  been  found to 
inhibit both IL-1 and IL-8 production in human monocytes4' 
and ne~trophils,"~  respectively. In the present study, the max- 
imum changes in plasma levels of  IFNy and IL-8 were in- 
versely correlated. 
The results from the present study may seem at variance 
with  some  recent  reports  showing  suppressive effects  of 
IVIG on IL-67  and TNFd  production in vitro. These discrep- 
ancies may have several explanations. First, Andersson et 
ai7 and Shimozato et a16 investigated the suppressive effects 
of  WIG on IL-6 and TNFa production in peripheral blood 
mononuclear cells (PBMCs) by adding IVIG to cell cultures 
less than 1 hour before LPS stimulation, which might have 
made the cells refractory to further stimulation. Indeed, in 
another in vitro study, IVIG showed enhancing effects on 
TNFa production from PBMC  when  given  alone and  24 
hours before  tim mu la ti on.^ Second, and even more important, 
cytokine production in vitro and in vivo differs considerably. 
In vivo, the measured circulating cytokine level is the out- 
come of the interplay between several cytokines, other circu- 
lating factors known to influence cytokine production (eg, 
hormones, neuropeptides), and a large numbers of cells (eg, 
PBMC, neutrophils, endothelial cells) not present in  an  in 
vitro system, making it very difficult to extrapolate results 
from simplified in vitro models to the much more complex 
in vivo situation. 
The present study of the in vivo effects of  IVIG has been 
performed  in  patients  with  primary  hypogammaglobuli- 
nemia, whereas most studies examining the in vitro effects 
of IVIG have been performed on samples from healthy blood 
donors.6-8  Although the main clinical feature in these patients 
is recurrent bacterial infections, particularly in the respira- 
tory tract, autoimmune disorders, noncaseating granulomata, 
lymphoid and gastrointestinal malignancies, and nonmalig- 
nant lymphoid hyperplasia are also c0mm0n.l~  We and others 
have previously shown that, in addition to the B-cell defect, 
many  of these patients are characterized by a state of chronic 
immune activation involving both  T-cells  and  monocyte/ 
macrophages, which is reflected in raised serum levels of 
cytokines  and  other  markers  of  immune  acti~ation.'~.'~.~~ 
Therefore, it is conceivable that findings in  these patients 
may have relevance to the clinical effects of IVIG in patients 
with autoimmune and other inflammatory disorders known 
to benefit from IVIG therapy. However, further studies in 
other patient populations will be  needed  to  confirm  and  ex- 
tend our findings. 
It is probable that a number of different mechanisms are 
responsible for the clinical effects of  WIG therapy seen in 
many diseases with immune pathogenesis. We believe that 
the demonstrated effects of  IVIG infusion on  the cytokine 
network,  particularly  the  induction  of  cytokines,  soluble 
cytokine receptors, and cytokine receptor antagonist with 
anti-inflammatory properties,  might  be  important for  the 
therapeutic effects of IVIG in several immune-mediated dis- 
orders, at least for rapidly occurring effects observed within 
days after start of  therapy. 
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